New hope for kids with severe psoriasis: drug trial launches
NCT ID NCT07529925
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests the drug adalimumab in 30 Chinese children aged 4 to 17 with severe plaque psoriasis. The goal is to see if the drug safely improves skin symptoms, measured by a 75% reduction in the Psoriasis Area and Severity Index at 16 weeks. Participants will be followed for up to 52 weeks to track long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE PLAQUE PSORIASIS IN CHINESE CHILDREN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.